Plasma cell dyscrasias (PCD) are due to an abnormal proliferation of a single clone of plasma or lymphoplasmacytic cells leading to secretion of immunoglobulin (Ig) or an Ig fragment, causing the dysfunction of multiple organs. Median survival of these patients has significantly improved over the last decade due to availability of treatment options such as high-dose melphalan with autologous stem cell transplantation and novel anti-myeloma agents. Renal transplantation has not traditionally been considered in these patients due to the previously limited prognosis, along with concerns relating to disease recurrence affecting the renal allograft and increased infection susceptibility following renal transplant due to immunosuppression and the PCD itself. However, with the increasing range of effective treatment options, renal transplantation could now be considered, especially in young patients with good performance status. It is therefore timely to reappraise the potential role of renal transplantation in end-stage renal disease due to multiple myeloma and other PCD. This review summarizes the literature relating to renal transplantation in PCD, including multiple myeloma, monoclonal Ig deposition disease and systemic AL amyloidosis, to attempt to identify patients who may benefit most from this approach and to explore areas for further development.

Keywords:
Plasma cell dyscrasias, Multiple myeloma, Monoclonal immunoglobulin deposition disease, Light chain deposition disease, Renal transplantation, Amyloidosis, Autologous stem cell transplantation
1.
Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 2004;351:1860–1873.
2.
BCSH and UKMF Guidelines on the Management and Diagnosis of Multiple Myeloma, 2010.
3.
Brenner H, Gondos A, Pulte D: Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010. Haematologica 2009;94:270–275.
4.
Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al: Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007;48:337–341.
5.
Basnayake K, Stringer SJ, Hutchison CA, Cockwell P: The biology of immunoglobulin-free light chains and kidney injury. Kidney Int 2011;79:1289–1301.
6.
Wirk B: Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 2011, pp 1–13.
7.
Korbet SM, Schwartz MM: Multiple myeloma. J Am Soc Nephrol 2006;17:2533–2545.
8.
Augustson BM, Begum G, Dunn JA, et al: Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219–9226.
9.
Rayner HC, Haynes AP, Thompson JR, et al: Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med 1991;79:517–525.
10.
Turesson I, Velez R, Kristinsson SY, Landgren O: Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830–834.
11.
Penfield J: Multiple myeloma in end-stage renal disease. Semin Dial 2006;19:329–334.
12.
Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
13.
Ludwig H, Adam Z, Greil R, et al: Reversal of acute renal impairment by bortezomib-doxorubicin-dexamethasone in multiple myeloma. Results from a phase II study. Haematologica 2009;94(suppl):154, abstr 385.
14.
Tosi P, Zamagni E, Cellini C, et al: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004;73:98–103.
15.
Leung N, Gertz MA, Zeldenrust SR, et al: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum-free light chains. Kidney Int 2008;73:1282–1288.
16.
Hutchison CA, Bradwell AR, Cook M, et al: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745–754.
17.
Haynes RJ, Read S, Collins GP, et al: Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant 2009;25:419–426.
18.
Hutchison CA, Cockwell P, Stringer S, et al: Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22:1129–1136.
19.
Hutchison CA, Cook M, Heyne N, et al: European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials. Clinicaltrials.gov/ct2/show/NCT00700531.
20.
Fudaba Y, Spitzer TR, Shaffer J, et al: Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006;6:2121–2133.
21.
Combined bone marrow transplantation (BMT) and renal transplant for multiple myeloma (MM) with end-stage renal disease (ESRD) NCT00854139 Clinical Trials.gov.
22.
Heher EC, Spitzer TR, Goes NB: Light chains: heavy burden in kidney transplantation. Transplantation 2009;87:947–952.
23.
Van Bommel EFH: Multiple myeloma treatment in dialysis-dependent patients: to transplant or not to transplant? Nephrol Dial Transplant 1996;11:1486–1487.
24.
De Lima JJ, Kourilsky O, Meyrier A, et al: Kidney transplant in multiple myeloma. Early recurrence in the graft with sustained normal renal function. Transplantation 1981;31:223.
25.
Walker F, Bear RA: Renal transplantation in light-chain multiple myeloma. Am J Nephrol 1983;3:34.
26.
Dagher F, Sammett D, Abbi R, et al: Renal transplantation in multiple myeloma. Case report and review of the literature. Transplantation 1996;62:1577–1580.
27.
Tsakiris DJ, Stel VS, Finne P, et al: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010;25:1200–1206.
28.
Spitzer TR, Sykes M, Tolkoff-Rubin N, et al: Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011;91:672–676.
29.
European Best Practice Guidelines for Renal Transplantation (Part 1). Nephrol Dial Transplant 2000;15(suppl 7).
30.
Heher EC, Spitzer TR, Goes NB: Light chains: heavy burden in kidney transplantation. Transplantation 2009;87:947–952.
31.
Leung N, Lager DJ, Gertz MA, et al: Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004;43:147–153.
32.
Royer B, Arnulf B, Martinez F, et al: High-dose chemotherapy in light chain or light and heavy chain deposition diseases. Kidney Int 2004;65:642–648.
33.
Hassoun H, Flombaum C, D’Agati VD, et al: High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplantation 2008;42:405–412.
34.
Lorenz E, Gertz M, Fervenza FC, et al: Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008;23:2052–2057.
35.
Girnius S, Seldin DC, Quillen K, et al: Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplant 2011;46:161–162.
36.
Bansal T, Hossain R, McKane W, Snowden JA: Safety and efficacy of high-dose melphalan and autologous stem cell transplantation prior to renal allograft in end-stage renal failure secondary to monoclonal immunoglobulin deposition disease. Cell Ther Transplant 2011;3:e.000091.01. doi:10.3205/ctt-2011-en-000091.01.
37.
Hartmann A, Holdaas H, Fauchald P, et al: Fifteen years’ experience with renal transplantation in systemic amyloidosis. Transplant Int 1992;5:15–18.
38.
Leung N, Griffin MD, Dispenzieri A, et al: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005;5:1660–1670.
39.
Sattianayagam PT, Gibbs SDJ, Gillmore JD, et al: Solid organ transplantation in AL amyloidosis. Am J Transplant 2010;10:2124–2131.
40.
Herrmann SM, Gertz MA, Stegall MD, et al: Long-term out comes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011;26:2032–2036.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.